Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Feb 12.

Published in final edited form as: Cancer Cell. 2018 Feb 12;33(2):292–308.e7. doi: 10.1016/j.ccell.2018.01.005

(A) qRT-PCR analysis of TAZ/YAP targets between control SNs, Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo paraspinal SNs. Data are as mean ± SEM (n = 3 independent experiments)

(B) Kaplan-Meier survival curves for control (n = 38), Lats1/2-deficient (n = 32) and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo mice (n = 25). p < 0.0001, between Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo; Log-rank test.

(C–D) Dermal tumor (C) and paraspinal/nerve tumor (D) number in control (n = 27), Lats1/2-deficient (n = 34) and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo (n = 18) mice. Green arrows: paraspinal tumors; Red arrows: dermal tumors.

(E) Immunostaining for Sox10 and Ki67 in 3-month-old control, Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo SNs. Scale bars, 50 µm.

(F–G) Total cell density (DAPI⁺ cells/mm²) (F) and Ki67⁺ Sox10⁺ SCs (G) in control, Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo SNs.

(H) Immunostaining for MBP and Sox10 in 3-month-old control, Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo SNs. Scale bars, 50 µm.

(I) The ratio of MBP⁺ area to total nerve area in control, Lats1/2-deficient and Lats1/2-def-Taz^Lo/LoYap1^Lo/Lo SNs.

Each data point is presented with mean ± SEM (n = 3–5 for each group; * p < 0.05, **p < 0.01, ***p < 0.001; One-way ANOVA with Tukey’s multiple comparisons test in A, F, G, I; Kruskal-Wallis test with Dunn’s multiple comparisons test in C, D).